Association of ITPA polymorphism with outcomes of peginterferon-&alpha; plus ribavirin combination therapy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 3

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastrointest Pharmacol Ther. Aug 6, 2013; 4(3): 54-60
Published online Aug 6, 2013. doi: 10.4292/wjgpt.v4.i3.54

Table 5 Multivariate analysis for predictive factors associated with SVR

HCV: Hepatitis C virus; IL28B: Interleukin 28B; SVR: Sustained virological response.

Citation: Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60
URL: https://www.wjgnet.com/2150-5349/full/v4/i3/54.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v4.i3.54

Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60 [PMID: 23919217 DOI: 10.4292/wjgpt.v4.i3.54]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.